Testing safusidenib, a daily pill, for newly found grade 3 gliomas with an IDH1 change
Original title: Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid-stage test to see if the drug works for this tumor type.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether a pill called safusidenib can help keep certain grade 3 brain tumors from growing.
Who this trial is for. This trial is for people with a newly found grade 3 oligodendroglioma or astrocytoma that has a gene change called IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary. Everyone in the study takes safusidenib, a pill that targets the tumor's IDH1 change.
Where it stands. The trial will check how many people's tumors have not grown after 12 months. It has not started taking patients yet. It has not reported any results.
What this means, and what it doesn't
What it could mean: Doctors are still working out where drugs like this fit in care for these tumors. This study aims to help answer that. If you have this tumor type, you could ask your care team whether this trial might fit you.
What it doesn't mean: This trial is a test, not a proven treatment. Taking part does not mean the drug will help you. It is not a cure, and no results are in yet.
Source: ClinicalTrials.gov, September 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.